Published in Transplant Proc on February 01, 1995
Enterococcus faecalis overcomes foreign body-mediated inflammation to establish urinary tract infections. Infect Immun (2012) 0.98
Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother (2003) 0.89
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol (2001) 12.00
Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science (1999) 8.63
Payment for donor kidneys: pros and cons. Kidney Int (2006) 7.57
Randomised trial of hysterectomy, endometrial laser ablation, and transcervical endometrial resection for dysfunctional uterine bleeding. BMJ (1994) 5.76
A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa. Int J Syst Bacteriol (1997) 5.28
CD1-restricted T cell recognition of microbial lipoglycan antigens. Science (1995) 5.03
Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science (1997) 4.96
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med (2004) 4.56
Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. J Biol Chem (1986) 4.52
Are general practitioners doing enough to promote healthy lifestyle? Findings of the Medical Research Council's general practice research framework study on lifestyle and health. Br Med J (Clin Res Ed) (1987) 4.48
Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med (2001) 4.07
Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol (1990) 3.85
Seasonal variation in arterial blood pressure. Br Med J (Clin Res Ed) (1982) 3.82
Immunological evaluation of a component isolated from Mycobacterium bovis BCG with a monoclonal antibody to M. bovis BCG. Infect Immun (1984) 3.46
Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med (1994) 3.25
Structure and antigenicity of the major specific glycolipid antigen of Mycobacterium leprae. J Biol Chem (1982) 3.11
Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. J Immunol (1992) 3.03
Structural studies on the type-specific antigens and lipids of the mycobacterium avium. Mycobacterium intracellulare. Mycobacterium scrofulaceum serocomplex. Mycobacterium intracellulare serotype 9. J Biol Chem (1979) 3.00
The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci U S A (1996) 2.83
Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun (1991) 2.77
A novel phenolic glycolipid from Mycobacterium leprae possibly involved in immunogenicity and pathogenicity. J Bacteriol (1981) 2.70
Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid. Nature (1984) 2.63
Characterization of the major membrane protein of virulent Mycobacterium tuberculosis. Infect Immun (1992) 2.61
The role of afferent lymphatics in the rejection of skin homografts. J Exp Med (1968) 2.60
HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant (2007) 2.50
Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem (2000) 2.43
Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study. Crit Care Med (1993) 2.42
Identification of atypical mycobacteria by thin-layer chromatography of their surface antigens. J Clin Microbiol (1978) 2.40
Immunologically privileged sites. Adv Immunol (1977) 2.35
Structural basis of capacity of lipoarabinomannan to induce secretion of tumor necrosis factor. Infect Immun (1992) 2.33
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med (1999) 2.33
Serological specificity of phenolic glycolipid I from Mycobacterium leprae and use in serodiagnosis of leprosy. Infect Immun (1983) 2.30
Thin-layer chromatography of lipid antigens as a means of identifying nontuberculous mycobacteria. J Clin Microbiol (1982) 2.29
Lipoarabinomannan of Mycobacterium tuberculosis. Capping with mannosyl residues in some strains. J Biol Chem (1992) 2.28
Mycobacterium leprae antigen-induced suppression of T cell proliferation in vitro. J Immunol (1987) 2.27
Aneurysm sac pressure measurements after endovascular repair of abdominal aortic aneurysms. J Vasc Surg (2001) 2.27
Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science (1990) 2.25
Evidence for the nature of the link between the arabinogalactan and peptidoglycan of mycobacterial cell walls. J Biol Chem (1990) 2.25
Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost (1992) 2.24
Peptidoglycolipid nature of the superficial cell wall sheath of smooth-colony-forming mycobacteria. J Bacteriol (1980) 2.21
Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Infect Immun (1988) 2.21
Evidence for the presence of a phosphatidylinositol anchor on the lipoarabinomannan and lipomannan of Mycobacterium tuberculosis. J Biol Chem (1990) 2.20
Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology (1995) 2.19
Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. J Biol Chem (1994) 2.18
Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother (1995) 2.17
Repeatability and validity of a modified activities of daily living (ADL) index in studies of chronic disability. Int Rehabil Med (1979) 2.14
Peptidoglycan-associated polypeptides of Mycobacterium tuberculosis. J Bacteriol (1990) 2.10
Phosphatidylinositol is an essential phospholipid of mycobacteria. J Biol Chem (2000) 2.03
Effects of isoniazid on the composition of mycobacteria, with particular reference to soluble carbohydrates and related substances. Biochem J (1967) 2.02
Structures of the glycopeptidolipid antigens from serovars in the Mycobacterium avium/Mycobacterium intracellulare/Mycobacterium scrofulaceum serocomplex. Eur J Biochem (1981) 2.01
Characterization of T cell antigens associated with the cell wall protein-peptidoglycan complex of Mycobacterium tuberculosis. J Immunol (1989) 2.01
The major native proteins of the leprosy bacillus. J Biol Chem (1990) 1.96
A major T cell antigen of Mycobacterium leprae is a 10-kD heat-shock cognate protein. J Exp Med (1992) 1.93
Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J Biol Chem (2000) 1.92
Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med (1993) 1.90
Evaluation of lipoarabinomannan for the serological diagnosis of tuberculosis. J Clin Microbiol (1990) 1.89
Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ (2000) 1.87
Evidence for species-specific lipid antigens in Mycobacterium leprae. Int J Lepr Other Mycobact Dis (1980) 1.87
Evidence for glycosylation sites on the 45-kilodalton glycoprotein of Mycobacterium tuberculosis. Infect Immun (1995) 1.86
Remedial therapy after stroke: a randomised controlled trial. Br Med J (Clin Res Ed) (1981) 1.84
Definition of the full extent of glycosylation of the 45-kilodalton glycoprotein of Mycobacterium tuberculosis. J Bacteriol (1996) 1.83
Structure, function and biogenesis of the cell envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug resistance; some thoughts and possibilities arising from recent structural information. Res Microbiol (1991) 1.82
Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet (1984) 1.81
Biosynthesis of the linkage region of the mycobacterial cell wall. J Biol Chem (1996) 1.76
B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes (1997) 1.75
Biosynthesis of mycobacterial lipoarabinomannan. J Biol Chem (1997) 1.74
Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis. Glycobiology (2001) 1.74
Stress and genetic testing for disease risk. Health Psychol (1997) 1.74
Most Mycobacterium leprae carbohydrate-reactive monoclonal antibodies are directed to lipoarabinomannan. Infect Immun (1987) 1.73
Structure of the specific oligosaccharides from the glycopeptidolipid antigens of serovars in the Mycobacterium avium-Mycobacterium intracellulare-Mycobacterium scrofulaceum complex. J Biol Chem (1981) 1.71
Role of the cell wall phenolic glycolipid-1 in the peripheral nerve predilection of Mycobacterium leprae. Cell (2000) 1.70
Location of the mycolyl ester substituents in the cell walls of mycobacteria. J Biol Chem (1991) 1.70
Clinical and epidemiological importance of typing of Mycobacterium avium complex isolates. J Clin Microbiol (1992) 1.69
Chemical basis of rough and smooth variation in mycobacteria. J Bacteriol (1989) 1.68
Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Antimicrob Agents Chemother (1995) 1.61
Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB. J Biol Chem (2001) 1.60
Drinking patterns in general practice patients. J R Coll Gen Pract (1987) 1.58
Extracellular fluid restoration in dehydration: a critique of rapid versus slow. Pediatr Nephrol (1999) 1.58
Isolation in high frequency of rough variants of Mycobacterium intracellulare lacking C-mycoside glycopeptidolipid antigens. J Bacteriol (1982) 1.57
Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob Agents Chemother (1996) 1.57
I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J Immunol (1999) 1.56
Antigen presenting function of class II MHC expressing pancreatic beta cells. Nature (1988) 1.56
Tumor necrosis factor production in patients with leprosy. Infect Immun (1992) 1.55
AIDS and Mycobacterium avium serovars in Sweden. Lancet (1989) 1.55
Popliteal artery aneurysms: current management and outcome. J Vasc Surg (1994) 1.55
Novel type-specific lipooligosaccharides from Mycobacterium tuberculosis. Biochemistry (1991) 1.55
Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant (2007) 1.55
Chemical synthesis and serology of disaccharides and trisaccharides of phenolic glycolipid antigens from the leprosy bacillus and preparation of a disaccharide protein conjugate for serodiagnosis of leprosy. Infect Immun (1984) 1.55
Isolation and characterization of the highly immunogenic cell wall-associated protein of Mycobacterium leprae. J Immunol (1989) 1.54
Rough morphological variants of Mycobacterium avium. Characterization of genomic deletions resulting in the loss of glycopeptidolipid expression. J Biol Chem (1993) 1.54
Structural features of the arabinan component of the lipoarabinomannan of Mycobacterium tuberculosis. J Biol Chem (1991) 1.53
Immunoreactivity of a 10-kDa antigen of Mycobacterium tuberculosis. J Immunol (1992) 1.52